Blockchain Registration Transaction Record

VERAXA Expands Human-Relevant Testing to Advance Cancer Pipeline

VERAXA Biotech (NASDAQ: VRXA) is expanding FDA-aligned New Approach Methodologies across its cancer pipeline, cutting animal use while advancing BiTAC T-cell engagers.

The shift toward New Approach Methodologies matters because it could reshape how cancer drugs are validated before they ever reach patients. By leaning on 3D spheroids, patient-derived xenograft models and computational tools, VERAXA aims to generate data that better predicts human responses—potentially reducing late-stage failures, which are among the costliest risks in oncology development. The dramatic reduction in animal use, from an estimated 200-plus mice to about 10 in one study, also aligns with growing regulatory and ethical pressure to modernize preclinical testing. For patients, more human-relevant models could mean faster, better-informed decisions about which antibody-based therapies advance to clinical trials. For investors, it signals a pipeline strategy built on efficiency and regulatory foresight as the FDA and global regulators increasingly embrace non-animal methods.